Characterization of SHP2 phosphatase as a therapeutic target in myeloproliferative neoplasms using an ex vivo bioreactor platform

被引：0
|
作者：
Vokalova, L. [1 ,2 ,3 ]
Garcia-Garcia, A. [2 ,3 ]
Reinhardt, E. [2 ,3 ]
Genty, L. [2 ,3 ]
Plantier, E. [2 ,3 ]
Jungius, S. [1 ,2 ,3 ]
Brkic, S. [2 ,3 ]
Rovo, A. [1 ]
Angelillo-Scherrer, A. [4 ,5 ]
Ivan, M. [2 ,3 ]
Meyer, S. C. [1 ,2 ,3 ,4 ,5 ]
机构：
[1] Univ Bern, Dept Biomed Res, Inselspital Bern, Bern, Switzerland
[2] Univ Basel, Basel, Switzerland
[3] Univ Hosp Basel, Dept Biomed, Basel, Switzerland
[4] Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland
[5] Cent Hematol Lab, Bern, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P433
引用
收藏
页码：223 / 223
页数：1
相关论文
共 50 条
  • [1] Ex vivo bioreactor platform for modeling MPN bone marrow and characterization of SHP2 phosphatase as a therapeutic target
    Vokalova, L.
    Garcia-Garcia, A.
    Reinhardt, E.
    Getty, L.
    Plantier, E.
    Jungius, S.
    Brkic, S.
    Rovo, A.
    Angelillo-Scherrer, A.
    Martin, I.
    Meyer, S.
    SWISS MEDICAL WEEKLY, 2023, 153 : 42S - 42S
  • [2] Targeting SHP2 phosphatase in Myeloproliferative Neoplasms
    Mali, Raghuveer Singh
    Chan, Rebecca
    Kapur, Reuben
    ONCOTARGET, 2012, 3 (10) : 1049 - 1051
  • [3] SHP2 phosphatase as a novel therapeutic target for melanoma treatment
    Zhang, Ruo-Yu
    Yu, Zhi-Hong
    Zeng, Lifan
    Zhang, Sheng
    Bai, Yunpeng
    Miao, Jinmin
    Chen, Lan
    Xie, Jingwu
    Zhang, Zhong-Yin
    ONCOTARGET, 2016, 7 (45) : 73817 - 73829
  • [4] Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
    Zeng, Li-Fan
    Zhang, Ruo-Yu
    Yu, Zhi-Hong
    Li, Sijiu
    Wu, Li
    Gunawan, Andrea M.
    Lane, Brandon S.
    Mali, Raghuveer S.
    Li, Xingjun
    Chan, Rebecca J.
    Kapur, Reuben
    Wells, Clark D.
    Zhang, Zhong-Yin
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (15) : 6594 - 6609
  • [5] SHP2 targeting inhibits MAPK pathway activation and improves therapeutic effects of ruxolitinib in myeloproliferative neoplasms
    Jungius, S.
    Mattei, S.
    Stivala, S.
    Szybinski, J.
    Vokalova, L.
    Rovo, A.
    Angelillo-Scherrer, A.
    Dirnhofer, S.
    Meyer, S.
    SWISS MEDICAL WEEKLY, 2023, 153 : 40S - 40S
  • [6] Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia
    Rongzhen Xu
    Cell Research, 2007, 17 : 295 - 297
  • [7] Shp2,a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia
    Rongzhen Xu~1 ~1Department of Hematology
    CellResearch, 2007, (04) : 295 - 297
  • [8] Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia
    Xu, Rongzhen
    CELL RESEARCH, 2007, 17 (04) : 295 - 297
  • [9] KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML
    Ma, Peilin
    Mali, Raghuveer
    Zeng, Li-Fan
    Martin, Holly
    Ramdas, Baskar
    He, Yantao
    Sims, Emily
    Ghosh, Joydeep
    Nabinger, Sarah C.
    Li, Shuo
    Munugalavadla, Veerendra
    Chatterjee, Anindya
    Sandusky, George
    Craig, Andrew
    Bunting, Kevin D.
    Feng, Gen-Sheng
    Chan, Rebecca J.
    Zhang, Zhong-Yin
    Kapur, Reuben
    BLOOD, 2011, 118 (21) : 396 - 396
  • [10] Significance of the Src homology 2 domain-containing phosphatase SHP2 in engaging MAPK pathway activation in myeloproliferative neoplasms
    Jungius, S.
    Mattei, S.
    Stivala, S.
    Szybinski, J.
    Dirnhofer, S.
    Neel, B.
    Meyer, S.
    SWISS MEDICAL WEEKLY, 2022, 152 : 34S - 35S
12345